K

    Kairos Pharma, Ltd. (KAPA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $0.24
    +0.00 (+1.22%)

    Market Cap: $5.62M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    25%(2/8)
    Avg Surprise
    -121.79%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.09
    Range$-0.09 - $-0.09
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.09+0.0%
    60d ago$-0.09+0.0%
    30d ago$-0.09+0.0%
    7d ago$-0.09+0.0%
    Current$-0.09
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Dec 31, 2026
    EPS Consensus$-0.12
    Range$-0.12 - $-0.12
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.12---
    Sep 26EST
    		-$-0.09---
    Jun 26
    		$-0.06$-0.09+33.33%Beat+25.0%
    Mar 26
    		$-0.08$-0.07-14.29%Miss-166.7%
    Dec 25
    		$-0.07$0.03-333.33%Miss-40.0%
    Sep 25
    		$-0.07$-0.07+0.00%Beat+30.0%
    Jun 25
    		$-0.08$-0.05-60.00%Miss-300.0%
    Mar 25
    		$-0.03$-0.02-50.00%Miss-
    Dec 24
    		$-0.05$-0.02-150.00%Miss-
    Sep 24
    		$-0.10$-0.02-400.00%Miss-
    Jun 24
    		$-0.02$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.86EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-114.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio11.98xQuick Ratio11.98x
    Trading Statistics
    BetaN/AAvg Volume570.29K
    52-Week High$2.1152-Week Low$0.22

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.27
    SMA 20$0.31
    SMA 50$0.33
    SMA 200$0.57
    EMA 10$0.27
    EMA 20$0.29
    EMA 50$0.34
    EMA 200$0.56

    MACD

    Line: -0.03Signal: -0.02Hist: -0.01

    ADX

    ADX: 28.1+DI: 13.4-DI: 30.9

    Aroon & PSAR

    Aroon Up36.0
    Aroon Down80.0
    PSAR$0.33

    Bollinger Bands

    Upper Band$0.41
    Lower Band$0.21
    %B Position6692%(Upper)
    Band Width0.16

    RSI (14-Day)

    Neutral
    34.2

    Momentum Oscillators

    Stoch %K13.2
    Stoch %D15.2
    Williams %R-85.7
    ROC (10d)-26.0%
    Momentum-0.08
    CCI (20d)-109.5
    MFI (14d)24.9

    Volatility Measures

    ATR (14d)$0.03(12.4%)
    StdDev (20d)0.05
    Hist Vol119.3%(High)

    Volume Flow

    VWAP$0.24
    OBV205.8M
    AD Line-216.4M
    CMF (20d)0.005

    Volume Metrics

    Avg Vol (20d)577.1K
    Vol Ratio0.6x
    VWMA (20d)$0.32

    Pivot Points

    R3$0.26
    R2$0.26
    R1$0.25
    Pivot Point$0.24
    S1$0.23
    S2$0.22
    S3$0.21

    Advanced Oscillators

    TSI-25.12
    Ultimate Osc37.1
    KST-168.47

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0$-120,000$0$0$0N/A$0$0$0$40,000$0
    Gross Profit$0$0$120,000$0$0$0N/A$0$0$0$-40,000$0
    Operating Expenses$1.42M$1.69M$1.42M$1.44M$1.46M$1.27M$1.45M$383,000$222,000$287,000$1.05M$287,000
    R&D$619,000$684,000$538,000$608,000$496,000$493,000$172,000$14,000$63,000$165,000$7,000$33,000
    SG&A$798,000$1.01M$877,000$827,000$960,000$773,000$1.28M$369,000$159,000$122,000$1.04M$254,000
    Operating Income$-1,417,000$-1,690,000$-1,415,000$-1,435,000$-1,456,000$-1,266,000$-1,451,000$-383,000$-222,000$-287,000$-1,089,000$-287,000
    Interest Income$0$0$50,000$37,000$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$-5,000$127,000$31,000$36,000$29,000$25,000
    Income Before Tax$-1,388,000$-1,654,000$-1,365,000$-1,398,000$-1,422,000$-1,262,000$-980,000$-1,047,000$-253,000$-323,000$-1,118,000$-312,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-1,388,000$-1,654,000$-1,365,000$-1,398,000$-1,422,000$-1,262,000$-980,000$-1,047,000$-253,000$-323,000$-1,118,000$-312,000
    EBITDA$-1,182,000$-1,430,000$-1,163,000$-735,000$-118,000$-1,226,000$-1,411,000$-765,000$-143,000$-247,000$-1,049,000$-287,000
    EBIT$-1,417,000$-1,690,000$-1,415,000$-1,435,000$-1,456,000$-1,266,000$-1,451,000$-920,000$-222,000$-287,000$-1,089,000$-287,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KAPA

    News

    Applied Optoelectronics, PDD Holdings And 3 Stocks To Watch Heading Into Monday

    As U.S. stock futures showed a downward trend on Monday morning, several companies are expected to capture investor attention. PDD Holdings Inc. is anticipated to release strong quarterly earnings, while Applied Optoelectronics Inc. announced a significant at-the-market equity offering, leading to a stock tumble. Xpeng Inc., Kairos Pharma Ltd. (which underwent a reverse stock split), and Gorilla Technology Group Inc. are also set to report earnings or have recent significant news impacting their stock performance.

    Sahm•8/24/26•
    Bearish

    KAIROS PHARMA ANNOUNCES 1-FOR-7 REVERSE STOCK SPLIT

    Kairos Pharma has announced a 1-for-7 reverse stock split of its common stock, effective August 23, 2026. The split will reduce the number of outstanding shares and increase the per-share trading price, while maintaining each stockholder's proportional ownership percentage. Stockholders will receive one new share for every seven old shares held.

    Moomoo•8/22/26•
    Neutral

    Kairos Pharma to conduct 1-for-7 reverse stock split

    Kairos Pharma announced a 1-for-7 reverse stock split of its common stock, effective September 1, 2026. This action is intended to reduce outstanding shares, increase the per-share trading price, and maintain compliance with NYSE American listing requirements. Fractional shares will be rounded up, and existing stock options and warrants will be proportionately adjusted.

    Investing.com•8/22/26•
    Neutral

    Kairos Pharma Announces 1-for-7 Reverse Stock Split to Meet NYSE American Listing Rules

    Kairos Pharma, Ltd. (NYSE American: KAPA) has announced a 1-for-7 reverse stock split, effective September 1, 2026, to increase its per-share trading price and comply with NYSE American listing requirements. This action will combine every seven shares into one, with fractional shares rounded up, and will not alter the underlying value of shareholder investments or proportional voting power. The split is a crucial step for the company to maintain its listing status.

    Minichart•8/22/26•
    Neutral

    Kairos Pharma to conduct 1-for-7 reverse stock split By Investing.com

    Kairos Pharma announced a 1-for-7 reverse stock split of its common stock, effective September 1, 2026, to reduce outstanding shares, increase per-share trading price, and maintain compliance with NYSE American listing requirements. Shares will trade on a split-adjusted basis under the existing symbol KAPA. Fractional shares will be rounded up to the nearest whole share for eligible holders.

    Investing.com Canada•8/21/26•
    Neutral

    Frequently Asked Questions About KAPA

    Does KAPA pay dividends?
    Kairos Pharma, Ltd. (KAPA) does not currently pay a regular dividend.
    What is KAPA's market cap?
    Kairos Pharma, Ltd. (KAPA) has a market capitalization of $5.62M with a current stock price of $0.24.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In